Rusan Pharma Fund 300 Crores in New API Facility in MP's Pithampur

A new active pharmaceutical ingredient (API) factory was opened by the pharmaceutical business Rusan Pharma. With an annual production capacity of 400 metric tons of APIs, this plant is estimated to generate over 300 employment. The factory is housed within the Pithampur Special Economic Zone (SEZ), and the business has spent Rs 300 crore in it.

The new facility will augment Rusan Pharma's existing API capacity, aiming to supply critical APIs to meet the increasing demand for its addiction treatment and pain management products in India and internationally, as per economic times The company is renowned for creating cutting-edge products, including native formulations of fentanyl, buprenorphine, and lidocaine transdermal patches for moderate to severe pain, and buprenorphine sublingual and buprenorphine Naloxone sublingual tablets for treating drug abuse. They also make transdermal nicotine patches for quitting smoking.

Kunal Saxena, managing director of Rusan Pharma, commented, “With an investment of about Rs 300 crore in two phases, this new API facility will expand our current API manufacturing capacity from 40 metric tonnes in Ankleshwar to 400 metric tonnes in Pithampur. Our new plant features five modular API manufacturing blocks with dedicated suites for finished API production.”

As per firm, 90% of the world's demand may be satisfied by the facilities where its completed formulations and APIs are now approved under Good Manufacturing Practices (GMP). 

Health Canada, the Therapeutic Goods Administration (TGA) of Australia, the South African Health Products Regulatory Authority (SAPHRA), the European Union (EU), the United Arab Emirates (UAE), and Russia are among the agencies that have granted Rusan Pharma GMP licenses.